Abstract
Many congenital or acquired nonmalignant diseases (NMDs) of the hematopoietic system can be potentially cured by allogeneic hematopoietic cell transplantation (HCT) with varying types of donor grafts, degrees of HLA matching, and intensity of conditioning regimens. Unique features that distinguish the use of allogeneic HCT in this population include higher rates of graft failure, immune-mediated cytopenias, and the potential to achieve long-term disease-free survival in a mixed chimerism state. Additionally, in contrast to patients with hematologic malignancies, a priority is to completely avoid graft-versus-host disease in patients with NMD because there is no theoretical beneficial graft-versus-leukemia effect that can accompany graft-versus-host responses. In this review, we discuss the current approach to each of these clinical issues and how emerging novel therapeutics hold promise to advance transplant care for patients with NMDs.
Original language | English (US) |
---|---|
Pages (from-to) | 3583-3593 |
Number of pages | 11 |
Journal | Blood |
Volume | 139 |
Issue number | 25 |
DOIs | |
State | Published - Jun 22 2022 |
Bibliographical note
Publisher Copyright:© 2022 American Society of Hematology
PubMed: MeSH publication types
- Journal Article
- Review
- Research Support, N.I.H., Extramural